Azilsartan Decreases Renal and Cardiovascular Injury in the Spontaneously Hypertensive Obese Rat

Abstract

Overall, these findings demonstrate kidney and heart protective effects of AZL-M in SHROB, and these effects were associated with its ability to lower blood pressure and improve endothelial function.

Hypertension Therapeutics Update: A Brief Clinical Summary on Azilsartan, Cilnidipine and Nebivolol

“…Azilsartan in the dose range of 40 to 80 mg/day produces significant reduction in the blood pressure levels and thus may reduce the chronic disease burden. 8,9 The optimal dose of azilsartan is 80 mg/day although a lower dosage (40 mg) can be utilized for patients on diuretics and other antihypertensive drugs. Angiotensin receptor blockers have a useful role in the management of hypertension and its complications.…”

Combination of Azilsartan Medoxomil and Chlorthalidone: Is It Possible to Fight Systemic Hypertension and Obesity Together?

“…Авторы исследования предполагают, что данный пре-парат может оказаться более эффективным, чем дру-гие представители этого класса у больных с ожире-нием или метаболическим синдромом. Похожие результаты были получены в работах Zhao M и Hye Khan, et al [16,17], в эксперименте с лабораторными крысами, страдавшими ожирением, азилсартан повышал чувствительность тканей к инсулину, улуч-шал сократительную функцию ЛЖ, обладал кардио-и нефропротективным действием. В исследовании Tarikuz Zaman AK, et al азилсартан оказывал кардио-протективное действие у лабораторных мышей с моделированным ожирением, инсулинорезистент-ностью и повышенной нагрузкой на ЛЖ [18].…”

Clinical Benefits of Azilsartan Beyond Blood Pressure Lowering?

“…Based on clinical studies conducted to date, azilsartan appears to be characterized by a superior ability to control 24 h systolic blood pressure relative to other widely used ARBs [1]. In the current issue of the journal, Khan et al report that azilsartan can decrease renal and cardiovascular injury in the spontaneously hypertensive obese (SHROB) rat [2]. Because the main reason for prescribing ARBs and other antihypertensive drugs is to control blood pressure and reduce the risk for target organ damage, the findings of Khan et al are of potential clinical interest.…”

“…Nevertheless, the ability of ARBs to protect against target organ damage and improve clinical outcomes is still considered to be largely mediated by their ability to decrease blood pressure. In addition to lowering blood pressure, Khan et al demonstrate that in the SHROB model, azilsartan medoxomil can protect against endothelial dysfunction as judged by its ability to improve vasodilatory responses to acetylcholine [2]. Impaired endothelial function might contribute to the pathogenesis of vascular disease and it is hoped that protection against endothelial dysfunction may promote improved clinical outcomes.…”

“…Impaired endothelial function might contribute to the pathogenesis of vascular disease and it is hoped that protection against endothelial dysfunction may promote improved clinical outcomes. Khan et al also found that azilsartan medoxomil treatment improved left ventricular (LV) function, LV hypertrophy, and reduced cardiac fibrosis in the SHROB model [2]. However, the extent to which these cardiovascular benefits might be related to pleiotropic actions of azilsartan beyond the strong antihypertensive effects of the drug remains to be clarified.…”